Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

References

• Maru Y. Molecular biology of chronic myeloid leukemia. Cancer Sci. 2012;103(9):1601–1610.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–3765.
   PubMed Web of Science ®Google Scholar
• Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007.
   PubMedGoogle Scholar
• Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008;2008(1):419–426.
   Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123(15):2317–2324.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765–1769.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–2309.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141–1145.
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141–154.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259.
   PubMed Web of Science ®Google Scholar
• Stein B, Smith BD. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010;32(5):804–820.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.
   PubMedGoogle Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–5411.
   PubMed Web of Science ®Google Scholar
• Hosoya K, Mochinaga S, Emoto A, et al. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. Int J Clin Oncol. 2015;20(6):1203–1210.
   PubMed Web of Science ®Google Scholar
• Jonsson S, Olsson B, Soderberg J, et al. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann Hematol. 2012;91(5):679–685.
   PubMed Web of Science ®Google Scholar
• Al-Dewik NI, Morsi HM, Samara MM, et al. Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol. 2016;10:CMO.S32822–104.
   Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Saglio G, Radich J, et al. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012;12(4):223–229.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Radich JP, Deininger M, Abboud CN, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1108–1135.
   PubMed Web of Science ®Google Scholar
• Santoleri F, Lasala R, Ranucci E, et al. Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematol. 2016;136(1):45–51.
   PubMed Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.
   PubMed Web of Science ®Google Scholar
• Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1(4):274–278.
   PubMedGoogle Scholar
• Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361–4368.
   PubMed Web of Science ®Google Scholar
• Santos-Macias JE, Baez de la Fuente E, Salas-Delgado A. [Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure]. Gac Med Mex. 2016;152(3):334–338.
   PubMed Web of Science ®Google Scholar
• Zackova D, Klamova H, Muzik J, et al. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Leuk Lymphoma. 2013;54(10):2310–2313.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861–2869.
   PubMed Web of Science ®Google Scholar
• Guerin A, Chen L, Wu EQ, et al. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin. 2012;28(7):1155–1162.
   PubMed Web of Science ®Google Scholar
• Smith BD, Liu J, Latremouille-Viau D, et al. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Curr Med Res Opin. 2016;32(5):817–827.
   PubMed Web of Science ®Google Scholar
• Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012;28(2):213–219.
   PubMed Web of Science ®Google Scholar
• Trivedi D, Landsman-Blumberg P, Darkow T, et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm. 2014;20(10):1006–1015.
   PubMed Web of Science ®Google Scholar
• Griffin JD, Guerin A, Chen L, et al. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis. Curr Med Res Opin. 2013;29(6):623–631.
   PubMed Web of Science ®Google Scholar
• Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869–874.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Muresan B, Mamolo C, et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019;35(9):1615–1622.
   PubMed Web of Science ®Google Scholar